Global

Open innovation is sometimes chaotic and often difficult to measure, but getting it right can give firms a real edge now and in the future.

Having a 'maverick' in your company can lead to problems as well as breakthroughs and innovations. Judith Germain outlines the value of harnessing a brilliant but wayward talent.

4 March, 2010

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

Anirban Ghosh and Siddharth Sawhney explain how research informatics tools can advance the speed and success of drug discovery research.

A corporate focus on negotiation can help organizations reap substantial and measurable benefit, writes Alison Morris.

February 26, 2010.

February 18, 2010.

Marketing excellence programmes are popular, important and frequently flawed, says Dr Brian D. Smith

February 16, 2010.

February 10, 2010.

Although representing a huge market, the EU also presents problems that hamper profitability- particularly when it comes to differing price regulations across member states.

January 29, 2010.

January 13, 2010.

Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations.

January 06, 2010.

January 04. 2010.

Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition.

Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal

With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?

06 August 2009

18 August 2009

11 August

3 August 2009

Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.